MARKET

ARDX

ARDX

Ardelyx
NASDAQ
5.47
-0.04
-0.64%
Pre Market: 4.570 -0.9 -16.45% 04:33 05/02 EDT
OPEN
5.51
PREV CLOSE
5.51
HIGH
5.65
LOW
5.39
VOLUME
36.34K
TURNOVER
--
52 WEEK HIGH
9.33
52 WEEK LOW
4.020
MARKET CAP
1.30B
P/E (TTM)
-32.8726
1D
5D
1M
3M
1Y
5Y
1D
Ardelyx Inc. Reports Strong Q1 2025 Growth
TipRanks · 4h ago
Ardelyx Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 4h ago
Ardelyx targets $240M-$250M in IBSRELA 2025 sales amid strong Q1 growth
Seeking Alpha · 6h ago
Ardelyx’s Growth Potential and Strategic Efforts Justify Buy Rating Despite Recent Setbacks
TipRanks · 10h ago
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics
NASDAQ · 10h ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 11h ago
Ardelyx falls 14% as Q1 results miss on both lines
Seeking Alpha · 11h ago
Ardelyx Q1 GAAP EPS $(0.17) Misses $(0.12) Estimate, Sales $74.11M Miss $78.80M Estimate
Benzinga · 12h ago
More
About ARDX
More
Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing first-in-class medicines. The Company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
Recently
Symbol
Price
%Change

Webull offers Ardelyx Inc stock information, including NASDAQ: ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.